PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Estradiol with norethisterone - Menopausal disorders

PAD Profile : Estradiol with norethisterone - Menopausal disorders

Keywords :
hormone replacement therapy, HRT, menopause, sequential combined therapy, continuous combined therapy, menopausal symptoms
Brand Names Include :
Evorel Sequi, Elleste Duet, Novofem, Trisequens, Elleste Duet Conti, Evorel Conti, Kliofem, Kliovance

Traffic Light Status

Status 1 of 8.

Status :
Green (see narrative)
Important
Formulations :
  • Patches
Important Information :
Evorel Sequi patches 2nd-line. Preferred option in women with risk factors for VTE or migraine.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 2 of 8.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
Elleste Duet tablets 2nd line. For women requiring sequential combined therapy but with poor cycle control on Femoston (1st-line).
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 3 of 8.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
Novofem tablets - Only use if there are product shortages with Elleste Duet
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
R
Comments :
No comments returned.
Documents :

Status 4 of 8.

Status :
Non Formulary
Important
Formulations :
  • Tablets
Important Information :
Trisequens tablets - consider changing to newer, 1st or 2nd line options.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 5 of 8.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
Elleste Duet Conti - 2nd line for women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line).
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 6 of 8.

Status :
Green (see narrative)
Important
Formulations :
  • Patches
Important Information :
Evorel Conti patches - preferred in women with risk factors for VTE or migraine. Otherwise use a 1st-line oral option.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 7 of 8.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
Kliofem tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 8 of 8.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
Kliovance tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Webpage
NHS Hormone Replacement Therapy Prescription Prepayment Certificate (HRT PPC)

Committee Recommendations

Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC has agreed a traffic light status and place in therapy for the treatments of menopausal disorders in line with the CKS recommenations:

Menopause | Health topics A to Z | CKS | NICE

Associated BNF Codes

06. Endocrine System
06.04.01. Female sex hormones and their modulators
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More